The immuno-oncology therapy developer has amassed at least $190m of overall funding following a series B round backed by Lilly Asia Ventures.
US-based immuno-oncology therapy developer Synthekine has raised $108m in a series B round featuring Lilly Asia Ventures, a corporate venturing vehicle for pharmaceutical firm Eli Lilly.
The round was co-led by investment firm Deerfield Management and asset manager Janus Henderson Investors.
RA Capital Management, Rock Springs Capital, Omega Funds, Samsara BioCapital, Canaan Partners, Emerson Collective, Column Group and its affiliate TCG Crossover, as well as an undisclosed healthcare investor also took part.
Founded in 2018, Synthekine is studying engineered cytokine…
